BeOne Medicines AG (ONC) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult...
Is BeOne Medicines AG stock overvalued or undervalued in 2026?
As of October 30, 2026, BeOne Medicines AG (ONC) trades at $370.33; its P/E is under review because the one we calculate differs from the one the data provider reports, according to Kaplio. Verdict under review: we are checking its data because the P/E we calculate differs from the one the data provider reports, and the verdict will return once they match.
Kaplio overview: BeOne Medicines AG
Market cap $40B · 52 weeks $260 – $386 (4 % below the high) · P/E under review · 2027 expected P/E 36.0× · Dividend none · Next earnings November 5, 2026 · expected EPS $1.90 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/E — (verdict under review).
- Balance sheet: Safe zone (solid).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
Verdict under review: we are checking its data because the P/E we calculate differs from the one the data provider reports, and the verdict will return once they match.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 5.3 %, fails.
- Market cap / Cash 8.9×, fails.
- Annual cash burn $10.34, passes.
- Total Debt 0.5×, passes.
Against its peers (reference peers) — BeOne Medicines AG: P/E 5.1×; EV/EBITDA 32.0×; ROIC 9.6 %; $39.6B. Genmab A/S (P/E 31.3×; EV/EBITDA 27.7×; ROIC 9.9 %; $35.1B), argenx SE (P/E 42.8×; EV/EBITDA 37.7×; ROIC 14.0 %; $55.6B), United Therapeutics Corporation (P/E 21.4×; EV/EBITDA 14.1×; ROIC 17.7 %; $25.7B).
Profitability
| Return on Equity | 14.27% |
| Return on Invested Capital | 9.63% |
| Return on Assets | 7.17% |
| Gross Margin | 87.82% |
| Operating Margin | 15.05% |
| Net Margin | 10.68% |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 3.40 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 5.25 |
Price Performance
| 1 month | +1.54% |
| 3 months | +17.58% |
| Year-to-date | +22.30% |
| 1 year | +20.55% |
| 3 years | +99.46% |
| 5 years | +3.87% |
| 10 years | +1011.46% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ONC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks